CMS’s November 5 final rule for the Medicare Drug Price Negotiation Program and Part D program is a major federal drug-cost policy update. The rule is directly relevant to cost because it governs how negotiated drug pricing and related Part D policies move from policy design toward operational implementation, with implications for Medicare spending and prescription affordability. This is materially different from prior posts because it is a final rule centered on drug negotiation and Part D, not a general CMS announcement about lowering drug costs.
